knowledge -WSS

knowledge

author：hotspot 2025-09-30 14:09:20 - browse：87

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Aspartame and sugar

hotspot

WSS

Bird flu researchers hone in on Finland’s mink farms

Couple fighting to bring baby home from Mexico are finally reunited

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Stanford president to resign after investigation of research

Trump got a 'target letter.' What is one and what does it mean?

Biogen’s boardroom scandal saddles CEO with first crisis

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Virginia high school admissions case could be legal follow

BMS, looking to build heart drug business, turns to AI for diagnosis

Guidelines to prevent youth baseball injuries need more muscle

Man who had jail sentence commuted by Trump arrested again

Duchenne breakthrough therapy leaves behind pioneering families

Resistance to cancer drugs: A new genetic explanation

Walensky prepares to leave CDC — and Congress — behind

Schizophrenia gene found to be linked to cells' energy dysfunction

Virginia high school admissions case could be legal follow

Megan Rapinoe shares emotional post following US Women's World Cup exit

hotspot

Bird flu researchers hone in on Finland’s mink farms

Maui wildfire now ranks as the fifth

After Optum profits sink, UnitedHealth makes changes

TikTok cracks down on users posting about weight loss drugs

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Timeline: How the deadly wildfires took over Maui day by day

knowledge

hotspot

Wikipedia

hotspot